PDL BioPharma Inc. (PDLI) Stock Quote

Detailed Quote for PDL BioPharma Inc. (PDLI) 
$ 6.39   -0.10 (-1.54%) Volume: 1.34 m 4:00 PM EST Feb 10, 2012
After Hours:  $ 6.35   -0.04 (-0.63%) Volume: 3.8 k 6:22 PM EST Feb 10, 2012
Today 5d 1m 3m 1y more
Last Price
6.39
Change $
0.10
Change %
1.54%
Tick
N/A
Bid
N/A
Bid Size
0
Ask
N/A
Ask Size
0
Open
6.45
High
6.48
Low
6.35
Prev Close
6.49
Last Trade
2/10/12
Volume
1.34 m
52 Wk Hi
6.70
52 Wk Low
4.66
Market Cap
893.54 m
Ex-Div Date
3/5/12
Div Rate
0.60
Yield
9.3897
Shares
139,834,559
EPS (TTM)
0.78
PE Ratio
8.20
Exchange
NGS
News and Media for PDL BioPharma Inc.  (PDLI) 
Sector News | Topic News
News for PDLI
Tue, Feb 07, 2012
7:00 AM PDL BioPharma to Present at the 14th Annual BIO CEO & Investor Conference - PR Newswire
Thu, Feb 02, 2012
5:07 PM PDL BioPharma Announces Exchange of Its 2.875% Convertible Senior Notes due February 15, 2015 - PR Newswire
Tue, Jan 24, 2012
7:00 AM PDL BioPharma Announces 2012 Regular Quarterly Dividends - PR Newswire
Thu, Jan 05, 2012
8:03 PM PDL BioPharma Announces Settlement and Final Results of its Exchange Offer - PR Newswire
7:00 AM PDL BioPharma to Present at the 30th Annual JP Morgan Healthcare Conference - PR Newswire
Tue, Jan 03, 2012
6:55 PM PDL BioPharma Announces Expiration and Preliminary Results of its Exchange Offer - PR Newswire
Mon, Dec 19, 2011
7:00 AM PDL BioPharma Provides Fourth Quarter 2011 Revenue Guidance of $72 Million - PR Newswire
Thu, Dec 15, 2011
7:00 AM PDL BioPharma Completes Regular Quarterly Dividend Payment - PR Newswire
Mon, Dec 12, 2011
7:30 AM PDL BioPharma Announces Departure of Chief Financial Officer - PR Newswire
7:00 AM PDL BioPharma Corrects Its Adjusted Conversion Rates for Its Convertible Notes - PR Newswire
Fri, Dec 09, 2011
8:00 AM BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors - Newsfile
Wed, Dec 07, 2011
7:00 AM PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes - PR Newswire
Tue, Nov 15, 2011
7:00 AM PDL BioPharma Inc. Announces Exchange Offer for Its 2.875% Convertible Senior Notes Due February 15, 2015 - PR Newswire
Wed, Nov 09, 2011
4:00 PM PDL BioPharma Announces Third Quarter 2011 Financial Results - PR Newswire
Tue, Nov 08, 2011
7:00 AM PDL BioPharma to Present at Lazard Capital Markets 8th Annual Healthcare Conference - PR Newswire
Wed, Nov 02, 2011
7:00 AM PDL BioPharma to Announce Third Quarter 2011 Financial Results on November 9, 2011 - PR Newswire
Wed, Oct 19, 2011
7:00 AM PDL BioPharma Retains Franklin Berger and Dr. Evan Bedil as Advisors to Assist with Implementation of Royalty Acquisition Strategy - PR Newswire
Thu, Sep 15, 2011
7:00 AM PDL BioPharma Completes Regular Quarterly Dividend Payment - PR Newswire
Tue, Sep 13, 2011
7:00 AM PDL BioPharma to Present at Upcoming Investor Conferences - PR Newswire
Thu, Sep 08, 2011
7:00 AM PDL BioPharma Provides Third Quarter 2011 Revenue Guidance of $83 Million - PR Newswire
More News for PDLI >>

Tags for PDL BioPharma Inc.

Research stocks or mutual funds related to PDL BioPharma Inc. by keywords or tags. Find companies that have a similar focus to PDLI. The keywords below have been associated to PDLI by either user submission or electronic means.

pharmaceutical sales data schering plough health care products biotechnology company biotech research king report on corporate governance corporate governance quotient biopharma leadership competencies pharmaceutical branding pharmaceutical industry strategy pharmaceutical publication pharmaceutical market corporate governance training Commercial Physical And Biological Research (8731) generic pharmaceutical niche pharmaceutical jobs in pharmaceutical pharmaceutical training biotechnology market patient software pharmaceutical research and development annual report leadership seminar pharmaceutical manufacturing company Biological Products pharmaceutical industry marketing corporate governance pharmaceutical tank pharmaceutical software pharma manufacturing corporate governance practices pharma license pharmaceutical supply chain novartis pharmaceuticals warrick pharmaceutical corporate governance issues pharmaceutical executives pharmaceutical ingredients no code of conduct pharmaceutical cro pharma consulting active pharmaceutical ingredients board of directors role good corporate governance pharmaceutical sales pharmaceutical distributors code of ethics patient care information corporate governance disclosure biotech corporation

 

NYE - Equity | NYE - ETF | AMX - Equity | AMX - ETF | NSD - Equity | NSD - ETF
NMF - ETF | NMF - Money Market Fund | NMF - Mutual Fund | OTC - Equity | OTO - Equity | OTO - ETF | OTO - Mutual Fund
CNQ - Equity | CBO - Equity | BDM - Equity | TSX - Equity | TSX - ETF | TSX - Mutual Fund | TSV - Equity | TSV - Mutual Fund

Dow Jones Composite Index | Dow Jones Industrial Avg | Dow Jones Transportation Avg | Dow Jones Utiliy Index | NASDAQ 100
Russell 1000 | Russell 2000 | Russell 3000 | Russell Microcap | Russell Midcap | S&P 500 | S&P MidCap 400 | S&P/TSX 60 | S&P/TSX MidCap

Recently Added Symbols   Firms   Find Financial Advisors

Advisors by Name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

RIAs by Name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Tags: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Insiders: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

All information displayed and available herein is on an "as is", "as available" basis and neither InvestorPoint.com nor any of its underlying service providers, information providers, licensors, employees, distributors or agents make any representations as to the suitability of our service or the materials for any purpose. The information is not intended for trading purposes or advice. We specifically disclaim any representations or warranties, express or implied, including, without limitation, any representations or warranties of merchantability or fitness for a particular purpose. InvestorPoint.com is not an investment adviser. We do not: (a) give investment advice, (b) advocate the purchase or sale of any security or investment and (c) provide, endorse or review any information or data contained herein. We do not guarantee the accuracy of the information and data supplied by information providers. We are not liable or responsible for the quality, accuracy or reliability of this information. You should always seek the assistance of a professional for investment advice.

Copyright © 2010 InvestorPoint.com All rights reserved.